Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.3 pts more than Nifty Smallcap 250 and 10.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Emcure Pharmaceuticals submitted audited standalone and consolidated results for Q4 and FY ended March 31, 2025. Statutory auditor BSR & Co. LLP issued an unmodified (clean) opinion on both sets of results. Standalone revenue from operations grew ~25% YoY to Rs. 4,381.9 crore, while standalone net profit nearly doubled to Rs. 317.1 crore from Rs. 160.8 crore. Consolidated revenue rose ~19% YoY to Rs. 7,963.3 crore and consolidated PAT grew ~34% to Rs. 707.5 crore. The board recommended a final dividend of Rs. 3 per share (30%) for FY25, subject to shareholder approval. The board also approved re-appointment of Dr. Mukund Gurjar as Whole-time Director for one year from August 28, 2025, appointment of SVD & Associates as secretarial auditor for five years, and incorporation of a new wholly-owned subsidiary 'Emcure Generics Private Limited' in Pune.
Strong double-digit revenue growth and a near-doubling of standalone profit, combined with a clean audit opinion and a 30% dividend, are positive for shareholders. The results are Emcure's first full year as a listed company (IPO listing was in July 2024), and the strong performance reflects a favourable launch year. The new subsidiary signals potential expansion in the generics space, which could support future growth.